Online inquiry

IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ473MR)

This product GTTS-WQ473MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ473MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11667MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ12719MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ11769MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ11584MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ4301MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ12467MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ5177MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ14241MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-6107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW